Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.

Uganda's experience in Ebola virus disease outbreak preparedness, 2018-2019.

Aceng JR, Ario AR, Muruta AN, Makumbi I, Nanyunja M, Komakech I, Bakainaga AN, Talisuna AO, Mwesigye C, Mpairwe AM, Tusiime JB, Lali WZ, Katushabe E, Ocom F, Kaggwa M, Bongomin B, Kasule H, Mwoga JN, Sensasi B, Mwebembezi E, Katureebe C, Sentumbwe O, Nalwadda R, Mbaka P, Fatunmbi BS, Nakiire L, Lamorde M, Walwema R, Kambugu A, Nanyondo J, Okware S, Ahabwe PB, Nabukenya I, Kayiwa J, Wetaka MM, Kyazze S, Kwesiga B, Kadobera D, Bulage L, Nanziri C, Monje F, Aliddeki DM, Ntono V, Gonahasa D, Nabatanzi S, Nsereko G, Nakinsige A, Mabumba E, Lubwama B, Sekamatte M, Kibuule M, Muwanguzi D, Amone J, Upenytho GD, Driwale A, Seru M, Sebisubi F, Akello H, Kabanda R, Mutengeki DK, Bakyaita T, Serwanjja VN, Okwi R, Okiria J, Ainebyoona E, Opar BT, Mimbe D, Kyabaggu D, Ayebazibwe C, Sentumbwe J, Mwanja M, Ndumu DB, Bwogi J, Balinandi S, Nyakarahuka L, Tumusiime A, Kyondo J, Mulei S, Lutwama J, Kaleebu P, Kagirita A, Nabadda S, Oumo P, Lukwago R, Kasozi J, Masylukov O, Kyobe HB, Berdaga V, Lwanga M, Opio JC, Matseketse D, Eyul J, Oteba MO, Bukirwa H, Bulya N, Masiira B, Kihembo C, Ohuabunwo C, Antara SN, Owembabazi W, Okot PB, Okwera J, Amoros I, Kajja V, Mukunda BS, Sorela I, Adams G, Shoemaker T, Klena JD, Taboy CH, Ward SE, Merrill RD, Carter RJ, Harris JR, Banage F, Nsibambi T, Ojwang J, Kasule JN, Stowell DF, Brown VR, Zhu BP, Homsy J, Nelson LJ, Tusiime PK, Olaro C, Mwebesa HG, Woldemariam YT.

Global Health. 2020 Mar 19;16(1):24. doi: 10.1186/s12992-020-00548-5.

3.

Adoption of COVID-19 triage strategies for low-income settings.

Ayebare RR, Flick R, Okware S, Bodo B, Lamorde M.

Lancet Respir Med. 2020 Apr;8(4):e22. doi: 10.1016/S2213-2600(20)30114-4. Epub 2020 Mar 11. No abstract available.

4.

Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study.

Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, Calcagno A, Castelnuovo B.

J Infect Dis. 2020 Feb 28. pii: jiaa088. doi: 10.1093/infdis/jiaa088. [Epub ahead of print]

PMID:
32112093
5.

Dolutegravir-associated hyperglycaemia in patients with HIV.

Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, Kiragga A, Lwanga IB, Castelnuovo B.

Lancet HIV. 2020 Feb 24. pii: S2352-3018(20)30042-4. doi: 10.1016/S2352-3018(20)30042-4. [Epub ahead of print] No abstract available.

PMID:
32105626
6.

Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.

Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P.

Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02394-19. doi: 10.1128/AAC.02394-19. [Epub ahead of print]

7.
8.

A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa.

Semakula JR, Mouton JP, Jorgensen A, Hutchinson C, Allie S, Semakula L, French N, Lamorde M, Toh CH, Blockman M, Sekaggya-Wiltshire C, Waitt C, Pirmohamed M, Cohen K.

PLoS One. 2020 Jan 29;15(1):e0227458. doi: 10.1371/journal.pone.0227458. eCollection 2020.

9.

Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in Uganda.

Mark NS, Rachel M, Kaimal A, Frank M, Harriet T, Isaac L, Lamorde M, Barbara C.

AIDS Res Treat. 2019 Dec 15;2019:9271450. doi: 10.1155/2019/9271450. eCollection 2019.

10.

Population Movement Patterns Among the Democratic Republic of the Congo, Rwanda, and Uganda During an Outbreak of Ebola Virus Disease: Results from Community Engagement in Two Districts - Uganda, March 2019.

Nakiire L, Mwanja H, Pillai SK, Gasanani J, Ntungire D, Nsabiyumva S, Mafigiri R; MID, Muneza N, Ward SE, Daffe Z, Ahabwe PB, Kyazze S; MBAIT, Ojwang J, Homsy J, Mclntyre E, Lamorde M, Walwema R, Makumbi I, Muruta A, Merrill RD.

MMWR Morb Mortal Wkly Rep. 2020 Jan 10;69(1):10-13. doi: 10.15585/mmwr.mm6901a3.

11.

The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research.

Naluyima P, Kayondo W, Ritchie C, Wandege J, Kagabane S, Tumubeere L, Kusiima B, Kibombo D, Atukunda S, Nanteza C, Nabirye H, Mugabi FB, Namuyanja S, Hatcher C, Rauch H, Mukembo M, Musinguzi P; JMEDICC Consortium, Sanders N, Turesson E, Cando C, Walwema R, Mimbe D, Hepburn J, Clark D, Lamorde M, Kibuuka H, Zaman S, Cardile AP, Martins KA.

PLoS Negl Trop Dis. 2019 Dec 19;13(12):e0007787. doi: 10.1371/journal.pntd.0007787. eCollection 2019 Dec. Review.

12.

Implementing routine physical function screening among elderly HIV-positive patients in Uganda.

Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B.

AIDS Care. 2019 Dec 17:1-4. doi: 10.1080/09540121.2019.1703888. [Epub ahead of print]

PMID:
31847531
13.

Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B.

AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x.

14.

Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.

Byakika-Kibwika P, Ssenyonga R, Lamorde M, Blessborn D, Tarning J.

BMC Infect Dis. 2019 Dec 3;19(1):1025. doi: 10.1186/s12879-019-4647-2.

15.

Evaluation of Infection Prevention and Control Readiness at Frontline Health Care Facilities in High-Risk Districts Bordering Ebola Virus Disease-Affected Areas in the Democratic Republic of the Congo - Uganda, 2018.

Biedron C, Lyman M, Stuckey MJ, Homsy J, Lamorde M, Luvsansharav UO, Wilson K, Gomes D, Omuut W, Okware S, Semanda JN, Kiggundu R, Bulwadda D, Brown V, Nelson LJ, Driwale A, Fagan R, Park BJ, Smith RM.

MMWR Morb Mortal Wkly Rep. 2019 Oct 4;68(39):851-854. doi: 10.15585/mmwr.mm6839a4.

16.

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).

Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S.

PLoS Med. 2019 Sep 20;16(9):e1002895. doi: 10.1371/journal.pmed.1002895. eCollection 2019 Sep.

17.

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.

Neary M, Chappell CA, Scarsi KK, Nakalema S, Matovu J, Achilles SL, Chen BA, Siccardi M, Owen A, Lamorde M.

J Antimicrob Chemother. 2019 Oct 1;74(10):3003-3010. doi: 10.1093/jac/dkz298.

PMID:
31299074
18.

Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".

Walimbwa S, Lamorde M, Waitt C, Amara A, Khoo S.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00593-19. doi: 10.1128/AAC.00593-19. Print 2019 Jun. No abstract available.

19.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

20.

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.

Laker EAO, Nabaggala MS, Kaimal A, Nalwanga D, Castelnuovo B, Musubire A, Kiragga A, Lamorde M, Ratanshi RP.

BMC Infect Dis. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5.

21.

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients.

Kaboggoza JP, Wang X, Neary M, Ayuso P, Sekaggya-Wiltshire C, Nakalema S, Owen A, McClure M, Lamorde M, Boffito M.

Open Forum Infect Dis. 2019 Jan 16;6(2):ofz035. doi: 10.1093/ofid/ofz035. eCollection 2019 Feb. No abstract available.

22.

Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda.

Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnouvo B, Nakasujja N, Calcagno A.

Oxf Med Case Reports. 2019 Feb 16;2019(2):omy132. doi: 10.1093/omcr/omy132. eCollection 2019 Feb.

23.

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.

Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M.

Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.

PMID:
30779340
24.

Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection.

Ellis J, Eneh PC, Ssebambulidde K, Rutakingirwa MK, Lamorde M, Rhein J, Cresswell FV, Boulware DR, Nicol MR.

Version 2. Wellcome Open Res. 2019 Jan 15 [revised 2019 Jan 1];3:111. doi: 10.12688/wellcomeopenres.14726.2. eCollection 2018.

25.

A Cross-Cutting Approach to Surveillance and Laboratory Capacity as a Platform to Improve Health Security in Uganda.

Lamorde M, Mpimbaza A, Walwema R, Kamya M, Kapisi J, Kajumbula H, Sserwanga A, Namuganga JF, Kusemererwa A, Tasimwa H, Makumbi I, Kayiwa J, Lutwama J, Behumbiize P, Tagoola A, Nanteza JF, Aniku G, Workneh M, Manabe Y, Borchert JN, Brown V, Appiah GD, Mintz ED, Homsy J, Odongo GS, Ransom RL, Freeman MM, Stoddard RA, Galloway R, Mikoleit M, Kato C, Rosenberg R, Mossel EC, Mead PS, Kugeler KJ.

Health Secur. 2018 Fall;16(S1):S76-S86. doi: 10.1089/hs.2018.0051.

PMID:
30480504
26.

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Gini J, Penchala SD, Amara A, Challenger E, Egan D, Waitt C, Lamorde M, Orrell C, Myer L, Khoo S, Else LJ.

Bioanalysis. 2018 Nov 19. doi: 10.4155/bio-2018-0085. [Epub ahead of print]

27.

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.

Walimbwa SI, Lamorde M, Waitt C, Kaboggoza J, Else L, Byakika-Kibwika P, Amara A, Gini J, Winterberg M, Chiong J, Tarning J, Khoo SH.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01310-18. doi: 10.1128/AAC.01310-18. Print 2019 Feb.

28.
29.

Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting.

Rachel M, Barbara C, Murphy C, Komujuni C, Nyakato P, Ocama P, Lamorde M, Easterbrook P, Ratanshi RP.

Hepatol Med Policy. 2018 Jan 6;3:3. doi: 10.1186/s41124-017-0030-3. eCollection 2018.

30.

Estimating the cost and cost-effectiveness for obstetric fistula repair in hospitals in Uganda: a low income country.

Epiu I, Alia G, Mukisa J, Tavrow P, Lamorde M, Kuznik A.

Health Policy Plan. 2018 Nov 1;33(9):999-1008. doi: 10.1093/heapol/czy078.

31.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
32.

High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM.

Wellcome Open Res. 2018 Jul 10;3:83. doi: 10.12688/wellcomeopenres.14691.1. eCollection 2018.

33.

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.

Lamorde M, Wang X, Neary M, Bisdomini E, Nakalema S, Byakika-Kibwika P, Mukonzo JK, Khan W, Owen A, McClure M, Boffito M.

Clin Infect Dis. 2018 Aug 16;67(5):785-790. doi: 10.1093/cid/ciy161.

34.

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.

Seden K, Kiiza D, Laker E, Arinaitwe WJ, Waitt C, Lamorde M, Khoo S.

J Antimicrob Chemother. 2018 Nov 1;73(11):3158-3161. doi: 10.1093/jac/dky298.

35.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

36.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

37.

Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.

Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher CV, Lamorde M, Scarsi KK, Siccardi M.

J Antimicrob Chemother. 2018 Apr 1;73(4):1004-1012. doi: 10.1093/jac/dkx515.

38.

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.

Waitt C, Olagunju A, Nakalema S, Kyohaire I, Owen A, Lamorde M, Khoo S.

J Antimicrob Chemother. 2018 Apr 1;73(4):1013-1019. doi: 10.1093/jac/dkx507.

39.

Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial.

Byakika-Kibwika P, Achan J, Lamorde M, Karera-Gonahasa C, Kiragga AN, Mayanja-Kizza H, Kiwanuka N, Nsobya S, Talisuna AO, Merry C.

BMC Infect Dis. 2017 Dec 28;17(1):794. doi: 10.1186/s12879-017-2924-5.

40.

Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda.

Kajumbula H, Fujita AW, Mbabazi O, Najjuka C, Izale C, Akampurira A, Aisu S, Lamorde M, Walwema R, Bahr NC, Meya DB, Boulware DR, Manabe YC.

Emerg Infect Dis. 2018 Jan;24(1):174-175. doi: 10.3201/eid2401.171112.

41.

Antimicrobial Resistance of Sterile Site Infections in Sub-Saharan Africa: A Systematic Review.

Workneh M, Katz MJ, Lamorde M, Cosgrove SE, Manabe YC.

Open Forum Infect Dis. 2017 Oct 6;4(4):ofx209. doi: 10.1093/ofid/ofx209. eCollection 2017 Fall.

42.

Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.

Kuznik A, Iliyasu G, Lamorde M, Mahmud M, Musa BM, Nashabaru I, Obaro S, Mohammed I, Habib AG.

PLoS One. 2017 Nov 30;12(11):e0188595. doi: 10.1371/journal.pone.0188595. eCollection 2017.

43.

Ebola Virus Epidemic in West Africa: Global Health Economic Challenges, Lessons Learned, and Policy Recommendations.

Elmahdawy M, Elsisi GH, Carapinha J, Lamorde M, Habib A, Agyie-Baffour P, Soualmi R, Ragab S, Udezi AW, Usifoh C, Usifoh S.

Value Health Reg Issues. 2017 Sep;13:67-70. doi: 10.1016/j.vhri.2017.08.003. Epub 2017 Sep 13.

PMID:
29073992
44.

Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.

Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A.

BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679.

45.

Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Chappell CA, Lamorde M, Nakalema S, Chen BA, Mackline H, Riddler SA, Cohn SE, Darin KM, Achilles SL, Scarsi KK.

AIDS. 2017 Sep 10;31(14):1965-1972. doi: 10.1097/QAD.0000000000001591.

46.

Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.

Waitt C, Diliiy Penchala S, Olagunju A, Amara A, Else L, Lamorde M, Khoo S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Aug 15;1060:300-307. doi: 10.1016/j.jchromb.2017.06.012. Epub 2017 Jun 17.

47.

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.

Boffito M, Lamorde M, Watkins M, Pozniak A.

Curr Opin HIV AIDS. 2017 Jul;12(4):339-342. doi: 10.1097/COH.0000000000000385. Review.

PMID:
28570367
48.

Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda.

Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schlech W, Kambugu A, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J.

AIDS. 2017 May 15;31(8):1196-1199. doi: 10.1097/QAD.0000000000001436. No abstract available.

PMID:
28441178
49.

The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, Scarsi KK.

Clin Pharmacol Ther. 2017 Sep;102(3):529-536. doi: 10.1002/cpt.667. Epub 2017 May 30.

50.

Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR.

J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.

Supplemental Content

Loading ...
Support Center